Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel

Table 2 Univariable and multivariable analyses for PFS data

	mPFS	HR univariable (95% CI)	p-value	HR multivariable (95% CI)	p-value
Entire cohort (95% CI)	5.2 (3.4–7.0)
Age ≤ 65	3.3
Age > 65	7.7	0.66 (0.40–1.09)	0.113	0.64 (0.37–1.10)	0.108
Locally advanced	6.8
Metastasized	4.5	1.22 (0.72–2.09)	0.434	1.55 (0.80–2.98)	0.190
ECOG PS 0	6.2
ECOG PS 1–2	4.5	1.08 (0.65–1.79)	0.769	1.16 (0.68–2.00)	0.579
Ca19–9 < median^a	5.4
Ca19–9 > median	5.1	1.15 (0.68–1.96)	0.597
Ca19–9 < 59xULN	4.2
Ca19–9 ≥ 59xULN	6.4	1.43 (0.82–2.49)	0.228
Albumin ≤37	5.1
Albumin > 37	6.1	0.72 (0.44–1.19)	0.194	0.93 (0.53–1.67)	0.826
TPK grade 0	3.1
TPK grade 1–4	7.0	0.31 (0.18–0.55)	< 0.001	0.49 (0.26–0.93)	0.029
Normal bilirubin^b	5.2
Elevated bilirubin	4.0	1.56 (0.56–4.34)	0.482
Dose reduction	6.4
Full dose	3.0	2.10 (1.13–3.93)	0.045	1.15 (0.57–2.33)	0.698
BM-tox grade 0–1	4.2
BM-tox grade 2–4	6.8	0.50 (0.29–0.85)	0.021
BM-tox grade 0–2	5.1
BM-tox grade 3–4	6.2	0.41 (0.20–0.87)	0.137	0.80 (0.41–1.56)	0.506
No leucocytosis^c	4.5
Leucocytosis	6.5	0.96 (0.57–1.63)	0.886

Median PFS in months. ^aMedian CA19–9 was 567kU/l, ^bS-bil < 26 μmole/L at treatment start, ^c < 8.8 × 10⁹/L at treatment start

ISSN: 1471-2407